There is a need for further characterisation of pre‐treatment correlates with pathological response in early HER2‐positive breast cancer, particularly in the era of dual HER2 inhibition and the potential for de‐escalation of treatment in appropriately selected patients. Here, ERBB2 is linked to breast cancer.